The presence of a BRAF mutation is a marker of poor prognosis in patients with mCRC and assosiated with a median overall survival(mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF wilde-type tumors. After first line therapy, treatment outcomes with standard therapy are poor in patients with BRAF mutated mCRC. Data from clinical trials are usually based on aselected patint population in order to provied standardized results in the given indication. BERIIG designed as prospectiveNIS Study will investigate the real world effectivness, qulity of life , safty and tolerability of encorafenib and cetuximab in BRAF mutant mCRC patients, who have recieved prior systemic therapy.